Personal Finance

Why Juno Therapeutics Stock Cooled Off in December

Chalkboard chart showing a positive trend turning negative.

What happened

Juno Therapeutics (NASDAQ: JUNO) , a clinical-stage cell therapy company, lost a bit of its luster last month by shedding 19.4% of its value, according to data from S&P Global Market Intelligence . Heading into December, Juno's shares were up by more than 200% for the year, showing the stark reversal in the company's fortunes.

What's the problem? Investors appear to be growing increasingly concerned that Juno's lead chimeric antigen receptor T cell therapy (CAR-T), JCAR017, won't be able to differentiate itself from Gilead Sciences ' (NASDAQ: GILD) Yescarta or Novartis ' (NYSE: NVS) Kymriah. Both of these pioneering CAR-Ts, after all, are already on the market.

Chalkboard chart showing a positive trend turning negative.

Image Source: Getty Images.

So what

Juno's JCAR017 is initially indicated for advanced non-Hodgkin lymphoma (NHL). The problem is that Gilead's Yescarta was approved in the U.S. for this indication late last year, and Novartis' Kymriah is expected to be approved for NHL early this year. So, Juno is roughly a year behind the industry leaders, implying that the biotech may have a hard time convincing doctors to switch to its therapy.

Now what

To do so, Juno is banking on JCAR017 being a more potent and safer product (i.e., best-in-class) than either Yescarta or Kymriah. While there haven't been any head-to-head trials conducted to properly assess JCAR017 against these other CAR-Ts, the data released last month at the annual American Society of Hematology meeting suggests that JCAR017 could, at least, be the safest of the bunch.

Unfortunately, the market apparently doesn't think safety will be enough to overcome Gilead or Novartis' first-mover advantage. That's not to say that the market is correct in its assessment of JCAR017's commercial prospects, but Juno's stock may have trouble gaining ground until its lead therapy proves otherwise.

10 stocks we like better than Juno Therapeutics

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Juno Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of January 2, 2018

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD NVS

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More